Rigel Pharmaceuticals (FRA:RI2) Cyclically Adjusted Book per Share: €4.06 (As of Mar. 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €33.59
GF Value €24.33
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Cyclically Adjusted Book per Share?

Rigel Pharmaceuticals FRA:RI2 +0.24% 76 Cyclically Adjusted Book per Share is €4.06 as of Mar. 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €24.33. The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rigel Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was €18.716. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €4.06 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Rigel Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was 2.10% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -25.30% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -24.50% per year. During the past 10 years, the average Cyclically Adjusted Book Growth Rate was -17.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Rigel Pharmaceuticals was -6.20% per year. The lowest was -28.20% per year. And the median was -11.90% per year.

As of today (2026-07-01), Rigel Pharmaceuticals's current stock price is €33.59. Rigel Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €4.06. Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 8.27.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rigel Pharmaceuticals was 11.85. The lowest was 0.52. And the median was 1.49.


Rigel Pharmaceuticals  (FRA:RI2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=33.59/4.06
=8.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rigel Pharmaceuticals was 11.85. The lowest was 0.52. And the median was 1.49.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rigel Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Rigel Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Cyclically Adjusted Book per Share Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.98 8.98 6.95 4.68 3.73

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.15 3.81 3.61 3.73 4.06

FRA:RI2 vs CADL, IMMX, AURA: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rigel Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rigel Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=18.716/330.2130*330.2130
=18.716

Current CPI (Mar. 2026) = 330.2130.

Rigel Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 6.936 241.018 9.503
201609 5.938 241.428 8.122
201612 5.255 241.432 7.187
201703 6.421 243.801 8.697
201706 5.002 244.955 6.743
201709 3.245 246.819 4.341
201712 5.793 246.524 7.760
201803 4.392 249.554 5.812
201806 6.355 251.989 8.328
201809 5.321 252.439 6.960
201812 5.777 251.233 7.593
201903 5.046 254.202 6.555
201906 4.134 256.143 5.329
201909 3.733 256.759 4.801
201912 2.883 256.974 3.705
202003 4.214 258.115 5.391
202006 3.323 257.797 4.256
202009 2.561 260.280 3.249
202012 1.652 260.474 2.094
202103 3.866 264.877 4.820
202106 3.309 271.696 4.022
202109 2.469 274.310 2.972
202112 1.566 278.802 1.855
202203 0.359 287.504 0.412
202206 -0.201 296.311 -0.224
202209 -1.159 296.808 -1.289
202212 -0.741 296.797 -0.824
202303 -1.305 301.836 -1.428
202306 -1.488 305.109 -1.610
202309 -1.711 307.789 -1.836
202312 -1.502 306.746 -1.617
202403 -1.661 312.332 -1.756
202406 -1.580 314.175 -1.661
202409 -0.749 315.301 -0.784
202412 0.177 315.605 0.185
202503 0.961 319.799 0.992
202506 3.960 322.561 4.054
202509 5.523 324.800 5.615
202512 18.258 324.054 18.605
202603 18.716 330.213 18.716

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €4.06 mean?
Rigel Pharmaceuticals (FRA:RI2) has a Cyclically Adjusted Book per Share of €4.06 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Rigel Pharmaceuticals' current Cyclically Adjusted Book per Share is €4.06. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Cyclically Adjusted Book per Share compare to CADL and IMMX?
Rigel Pharmaceuticals' Cyclically Adjusted Book per Share of €4.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Cyclically Adjusted Book per Share is €4.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Cyclically Adjusted Book per Share of €4.06. The stock's GF Value™ is €24.33, compared to a current price of €33.59 — trading 38.1% above its estimated fair value. The current Cyclically Adjusted Book per Share is €4.06. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Cyclically Adjusted Book per Share is €4.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €33.59 is trading 38.1% above its estimated GF Value™ of €24.33.

Key valuation signals for FRA:RI2:

  • Cyclically Adjusted Book per Share: €4.06
  • GF Value™: €24.33 vs. price of €33.59 (38.1% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.59
Price
€24.33
GF Value